abstract：INTRODUCTION:Obinutuzumab is a novel humanized type II glycoengineered anti-CD20 antibody approved for first-line treatment of chronic lymphocytic leukemia (CLL) in combination with chlorambucil and for treatment of rituximab-refractory follicular lymphoma (FL). Areas covered: We describe current preclinical and clinic...

journal_title：Expert opinion on investigational drugs

authors： Klein C,Bacac M,Umana P,Fingerle-Rowson G

更新日期：2017-10-01 00:00:00

abstract：INTRODUCTION:Type 2 diabetes is a chronic metabolic disease characterized by persistent hyperglycemia resulting from progressive deficient of insulin in patients with a background of insulin resistance. Current treatment algorithms recommended by American Diabetes Association/The European Association for the Study of D...

journal_title：Expert opinion on investigational drugs

authors： Tan X,Cao X,Zhou M,Zou P,Hu J

更新日期：2017-09-01 00:00:00

abstract：INTRODUCTION:Axial spondyloarthritis (AxS pA) is a chronic inflammatory disease for which, until recently, there were no valid therapeutic alternatives to TNF-α blocking agents. This unmet clinical need led to explore several therapeutic targets, from proinflammatory cytokines to intracellular signaling systems. The re...

journal_title：Expert opinion on investigational drugs

authors： Clavel G,Boissier MC,Sigaux J,Semerano L

更新日期：2017-07-01 00:00:00

abstract：INTRODUCTION:Erectile function is an important aspect in the quality of life of many men. For men with erectile dysfunction (ED), a spectrum of treatment options exists. Novel therapies for ED are currently being developed in order to delay surgical placement of a penile prosthesis - the final step in the management of...

journal_title：Expert opinion on investigational drugs

authors： Smith-Harrison L,Starke NR,Smith RP,Kovac JR

更新日期：2017-06-01 00:00:00

abstract：INTRODUCTION:Basal-like breast cancer is characterized by being triple negative and aggressive. Defects in DNA repair is a promising therapeutic target as BRCA alterations are found in 11 to 42% of these tumors, with a frequency varying according to family history and ethnicity. The oral PARP inhibitors exploit this de...

journal_title：Expert opinion on investigational drugs

authors： Robert M,Frenel JS,Gourmelon C,Patsouris A,Augereau P,Campone M

更新日期：2017-06-01 00:00:00

abstract：INTRODUCTION:Crizotinib is a first-in-class ALK tyrosine kinase inhibitor (TKI), which has proven its superiority over standard platinum-based chemotherapy for the first-line therapy of ALK-rearranged non-small cell lung cancer (NSCLC) patients. The development of acquired resistance to crizotinib represents an ongoing...

journal_title：Expert opinion on investigational drugs

authors： Karachaliou N,Santarpia M,Gonzalez Cao M,Teixido C,Sosa AE,Berenguer J,Rodriguez Capote A,Altavilla G,Rosell R

更新日期：2017-06-01 00:00:00

abstract：INTRODUCTION:Since the discovery of the activating V617F mutation in Janus kinase 2 (JAK2), a number of pharmacologic inhibitors of JAK2 have entered clinical trials for patients with myelofibrosis. However, ruxolitinib, approved in 2011, remains the only one currently available for treatment of myelofibrosis, with man...

journal_title：Expert opinion on investigational drugs

authors： Bose P,Abou Zahr A,Verstovsek S

更新日期：2017-06-01 00:00:00

abstract：INTRODUCTION:Frontline chemotherapy is successful against chronic lymphocytic leukemia (CLL), but results in untoward toxicity. Further, prognostic factors, cytogenetic anomalies, and compensatory cellular signaling lead to therapy resistance or disease relapse. Therefore, for the past few years, development of targete...

journal_title：Expert opinion on investigational drugs

authors： Vangapandu HV,Jain N,Gandhi V

更新日期：2017-05-01 00:00:00

abstract：INTRODUCTION:Epidermal growth factor receptor (EGFR) targeted treatment has been evaluated but has not shown a clear clinical benefit for breast cancer. This review article aims to consider the knowledge of the biological background of EGFR pathways in dissecting clinical studies of EGFR targeted treatment in breast ca...

journal_title：Expert opinion on investigational drugs

authors： Matsuda N,Lim B,Wang X,Ueno NT

更新日期：2017-04-01 00:00:00

abstract：INTRODUCTION:Alzheimer's disease (AD) is the most common cause of dementia in the elderly. Pharmacological treatment of AD includes Anticholinesterase Inhibitors (AChEIs) for mild-moderate AD, and memantine for severe AD. These drugs provide mainly symptomatic short-term benefits without clearly influencing the progres...

journal_title：Expert opinion on investigational drugs

authors： Galimberti D,Scarpini E

更新日期：2017-01-01 00:00:00

abstract：INTRODUCTION:Noise-induced hearing loss (NIHL) due to industrial, military, and recreational noise exposure is a major, but also potentially preventable cause of acquired hearing loss. For the United States it is estimated that 26 million people (15% of the population) between the ages of 20 and 69 have a high-frequenc...

journal_title：Expert opinion on investigational drugs

authors： Sha SH,Schacht J

更新日期：2017-01-01 00:00:00

abstract：INTRODUCTION:Heat shock proteins (Hsps) are part of a complex network of chaperone proteins that are critically involved in the conformational maturation of intracellular proteins and regulate their degradation via the proteasome system Hsps (especially Hsp70 and Hsp90) are upregulated in many cancers and are potential...

journal_title：Expert opinion on investigational drugs

authors： Subramaniam DS,Warner EA,Giaccone G

更新日期：2017-01-01 00:00:00

abstract：INTRODUCTION:The Philadelphia chromosome negative myeloproliferative neoplasms (MPN) mainly comprise polycythemia vera (PV), essential thrombocythemia (ET) and myelofibrosis (MF, primary or post-PV/ET). Therapy in PV and ET focuses on minimizing thrombosis and bleeding risk, while in MF, prolongation of survival is an ...

journal_title：Expert opinion on investigational drugs

authors： Bose P,Verstovsek S

更新日期：2016-12-01 00:00:00

abstract：INTRODUCTION:In asthma, most commonly, 'conventional' anti-inflammatory medications represented by inhaled corticosteroids and leukotriene inhibitors are effective. In some patients however additional inhibition of the airways inflammation is necessary. Such compounds might be molecules inhibiting specifically certain ...

journal_title：Expert opinion on investigational drugs

authors： Antoniu SA

更新日期：2016-10-01 00:00:00

abstract：INTRODUCTION:Diabetic macular edema (DME) and proliferative diabetic retinopathy (PDR) are the two complications of diabetes that cause visual loss and blindness. Laser photo-coagulation in the past was used to prevent progression of disease to these advanced stages. Advances in pathophysiologic understanding of DME an...

journal_title：Expert opinion on investigational drugs

authors： Tolentino MS,Tolentino AJ,Tolentino MJ

更新日期：2016-09-01 00:00:00

abstract：INTRODUCTION:Asthma is a chronic inflammatory disease characterized by bronchial hyper-reactivity. Although many currently available treatment regimens are effective, poor symptom control and refractory severe disease still represent major unmet needs. In the last years, numerous molecular therapeutic targets that inte...

journal_title：Expert opinion on investigational drugs

authors： Santus P,Radovanovic D

更新日期：2016-09-01 00:00:00

abstract：INTRODUCTION:Although the combination of an anti-CD20 monoclonal antibody and chemotherapy has widely improved survival of patients with B-cell lymphoma, the disease still relapses. A better understanding of the biology of lymphomas has highlighted the role of the cell of origin in response to treatment and outcome. Le...

journal_title：Expert opinion on investigational drugs

authors： Garciaz S,Coso D,Schiano de Colella JM,Bouabdallah R

更新日期：2016-09-01 00:00:00

abstract：INTRODUCTION:Asthma is a common respiratory disease characterized by airway inflammation, bronchoconstriction and airway hyperresponsiveness and symptoms such as coughing, wheezing, shortness of breath and chest tightness. Allergic rhinitis is a common comorbidity in asthma and glucocorticoids are the key stone in the ...

journal_title：Expert opinion on investigational drugs

authors： Meteran H,Backer V

更新日期：2016-08-01 00:00:00

abstract：INTRODUCTION:In the treatment of advanced/metastatic head and neck cancer (HNC), resistance to chemotherapy and to anti-EGFR agents remains a major issue, and new molecular drugs are eagerly awaited. Over the last decade, knowledge of the genetic landscape of HNC has rapidly grown. However, no tailored therapeutic inte...

journal_title：Expert opinion on investigational drugs

authors： Bossi P,Alfieri S

更新日期：2016-07-01 00:00:00

abstract：INTRODUCTION:Ewing sarcoma family tumors (ESFT) are a group of aggressive diseases, characterized histologically by small, round, blue cells and genetically by translocation involving EWS and ETS partner genes. The current treatment of localized Ewing sarcoma (ES) requires a multi-disciplinary approach, including multi...

journal_title：Expert opinion on investigational drugs

authors： Vornicova O,Bar-Sela G

更新日期：2016-06-01 00:00:00

abstract：INTRODUCTION:Recurrent and/or metastatic head and neck squamous cell carcinoma (HNSCC) has a dismal prognosis. With the emergence of monoclonal antibodies and tyrosine kinase inhibitors (TKI) targeting the epidermal growth factor receptor (EGFR), several drugs were developed and tested in HNSCC. To date, the monoclonal...

journal_title：Expert opinion on investigational drugs

authors： Elicin O,Ozsahin M

更新日期：2016-06-01 00:00:00

abstract：INTRODUCTION:Due to improvements in our understanding of the pathogenesis of systemic lupus erythematosus (SLE), several target drugs have been and are being developed. One of the possible targets in SLE is co-stimulation between antigen-presenting cells and T cells. Abatacept is a co-stimulation moderator approved for...

journal_title：Expert opinion on investigational drugs

authors： Pimentel-Quiroz VR,Ugarte-Gil MF,Alarcón GS

更新日期：2016-01-01 00:00:00

abstract：INTRODUCTION:Stroke is the second leading cause of death worldwide and the leading cause of adult neurological disability. Despite advances in stroke unit care, and increasing use of thrombolysis, there remains an urgent need for safe and effective treatments for acute ischaemic stroke. However, this is against a backd...

journal_title：Expert opinion on investigational drugs

authors： Smith CJ,Denes A,Tyrrell PJ,Di Napoli M

更新日期：2015-05-01 00:00:00

abstract：INTRODUCTION:Posttraumatic stress disorder (PTSD) is a prevalent, chronic and disabling anxiety disorder that may develop following exposure to a traumatic event. There is currently no effective pharmacotherapy for PTSD and therefore the discovery of novel, evidence-based treatments is particularly important. This revi...

journal_title：Expert opinion on investigational drugs

authors： Ragen BJ,Seidel J,Chollak C,Pietrzak RH,Neumeister A

更新日期：2015-05-01 00:00:00

abstract：INTRODUCTION:The fast actions of the excitatory neurotransmitter glutamate are mediated by glutamate-gated ion channels (ionotropic Glu receptors). Metabotropic glutamate receptors (mGlus) are coupled to second messenger pathways via G proteins and modulate glutamatergic and GABAergic neurotransmission. Of the eight di...

journal_title：Expert opinion on investigational drugs

authors： Raber J,Duvoisin RM

更新日期：2015-04-01 00:00:00

abstract：INTRODUCTION:There has been a striking increase in the emergence of multidrug-resistant pathogens in recent times. Delafloxacin is a novel, broad-spectrum fluoroquinolone with antimicrobial activity against resistant Gram-positive, Gram-negative and anaerobic organisms. It has the potential to treat a variety of infect...

journal_title：Expert opinion on investigational drugs

authors： Bassetti M,Della Siega P,Pecori D,Scarparo C,Righi E

更新日期：2015-03-01 00:00:00

abstract：INTRODUCTION:Multiple myeloma (MM) remains an incurable malignancy indicating a need for continued investigation of novel therapies. Recent studies have highlighted the role of cyclin-dependent kinases (CDK) in the pathogenesis of MM. PD0332991 (Palbociclib) is an orally bioavailable, highly selective inhibitor of the ...

journal_title：Expert opinion on investigational drugs

authors： Altenburg JD,Farag SS

更新日期：2015-02-01 00:00:00

abstract：INTRODUCTION:Available drugs partially attenuate the hyperglycemia characteristic of diabetes. However, successful approaches to treat the root cause or to cure or prevent diabetes remain elusive. Drug discovery and development programs continue to focus on mechanisms that impact specific symptoms of diabetes. In 2014,...

journal_title：Expert opinion on investigational drugs

authors： Colca JR

更新日期：2015-01-01 00:00:00

abstract：:Introduction: The armamentarium of antileishmanial drugs is small. It is further being threatened by the development of resistance and decreasing sensitivity to the available drugs. The development of newer drugs is sorely needed. Areas covered: The authors have based their review on a literature search performed usin...

journal_title：Expert opinion on investigational drugs

authors： Sundar S,Chakravarty J

更新日期：2015-01-01 00:00:00

abstract：INTRODUCTION:The unmet need and the growing prevalence of hyperuricemia and its complications worldwide have pushed investigators to identify new agents to manage hyperuricemia. AREAS COVERED:This review discusses the drugs in preclinical and early clinical trials for hyperuricemia, their mechanisms of action and avai...

journal_title：Expert opinion on investigational drugs

authors： Shahid H,Singh JA

更新日期：2015-01-01 00:00:00

abstract：INTRODUCTION:About 185,000,000 people worldwide are chronically infected with hepatitis C virus (HCV). Currently, the most successful HCV infection antiviral therapies reduce the chance of progression towards the advanced phases of the hepatopathy (liver cirrhosis, hepatocellular carcinoma and death). Recently, however...

journal_title：Expert opinion on investigational drugs

authors： Gentile I,Zappulo E,Buonomo AR,Maraolo AE,Borgia G

更新日期：2015-01-01 00:00:00

abstract：INTRODUCTION:Soft tissue sarcomas (STS) are a rare and difficult to treat malignancy. Efforts to utilize targeted therapy have been ongoing for the last decade and have resulted in the approval of pazopanib for treatment of advanced disease. Although several other agents have been investigated, the inability to predict...

journal_title：Expert opinion on investigational drugs

authors： Mohindra N,Agulnik M

更新日期：2015-01-01 00:00:00

abstract：INTRODUCTION:Currently, there is no cure available for the hereditary neurodegenerative disease proximal spinal muscular atrophy (SMA), which is the number one genetic killer in early childhood. However, growing knowledge of SMA pathophysiology has opened new avenues for potential therapeutic interventions. AREAS COVE...

journal_title：Expert opinion on investigational drugs

authors： Kaczmarek A,Schneider S,Wirth B,Riessland M

更新日期：2015-01-01 00:00:00

abstract：INTRODUCTION:Sepsis with Bacillus anthracis infection has a very high mortality rate despite appropriate antibiotic and supportive therapies. Over the past 15 years, recent outbreaks in the US and in Europe, coupled with anthrax's bioterrorism weapon potential, have stimulated efforts to develop adjunctive therapies to...

journal_title：Expert opinion on investigational drugs

authors： Ohanjanian L,Remy KE,Li Y,Cui X,Eichacker PQ

更新日期：2015-01-01 00:00:00

abstract：INTRODUCTION:Inhaled corticosteroids are the only drugs that effectively suppress the airway inflammation, but they can induce considerable systemic and adverse effects when they are administered chronically at high doses. Consequently, the pharmaceutical industry is still searching for newer entities with an improved ...

journal_title：Expert opinion on investigational drugs

authors： Cazzola M,Coppola A,Rogliani P,Matera MG

更新日期：2015-01-01 00:00:00

abstract：INTRODUCTION:Epithelial ovarian cancer (EOC) is the fourth commonest cause of female cancer death in the developed world. Although progress in treatment has improved survival, ∼ 80% of patients with advanced EOC will experience a recurrence and eventually will become resistant to chemotherapy. The aim of treatment for ...

journal_title：Expert opinion on investigational drugs

authors： Marchetti C,Ledermann JA,Benedetti Panici P

更新日期：2015-01-01 00:00:00

abstract：INTRODUCTION:Peripheral arterial disease (PAD) is a manifestation, and marker of severity, of a generalized atherosclerotic process. Antiplatelet therapy is recommended to prevent cardiovascular events but much of the evidence to support this is drawn from studies on older drugs. AREAS COVERED:In this review, the auth...

journal_title：Expert opinion on investigational drugs

authors： Chong AY,So DY

更新日期：2014-12-01 00:00:00

abstract：INTRODUCTION:The prognosis for patients with oesophagogastric (OG) cancer remains poor, with a median survival of approximately 9 - 11 months for patients with metastatic disease. However, a more personalised approach to treatment, using drugs tailored to the molecular characteristics of patients' tumours, has the pote...

journal_title：Expert opinion on investigational drugs

authors： Moorcraft SY,Chau I

更新日期：2014-10-01 00:00:00

abstract：INTRODUCTION:EGFR has been implicated in various malignancies such as NSCLC, breast, head and neck, and pancreatic cancer. Numerous drugs have been developed in order to target the tyrosine domain of EGFR as an approach in cancer treatment. AREAS COVERED:This article focuses on the different generations of EGFR tyrosi...

journal_title：Expert opinion on investigational drugs

authors： Lee CC,Shiao HY,Wang WC,Hsieh HP

更新日期：2014-10-01 00:00:00

abstract：INTRODUCTION:Lupus nephritis (LN) is a significant contributor to morbidity and mortality in systemic lupus erythematosus (SLE). Current therapies for LN are limited by significant toxicities and high rates of relapse. A clear and present need exists for the development of effective, targeted and well-tolerated treatme...

journal_title：Expert opinion on investigational drugs

authors： Thanarajasingam U,Niewold TB

更新日期：2014-10-01 00:00:00